Personalis is said to have attracted takeover interest from Merck

Personalis shares rose ~4% in premarket trading after reports revealed takeover interest from Merck and two other bidders. The company is exploring a potential sale, having hired Cooley for legal counsel and Centerview and TD Securities as bankers to evaluate offers. Personalis, a cancer test developer with a $1.6B market cap, has seen its stock rally nearly 100% this year despite recording an $81.3M net loss last year.